A Glimpse Of Light For Kolon As US Invossa Trials To Resume

FDA Lifts Clinical Hold

Following the long-awaited decision from the US FDA, Kolon TissueGene will resume Phase III clinical trials of the cell and gene therapy for degenerative osteoarthritis TG-C (Invossa) in the US this year.

In Modern Laboratory Senior Female Scientist Has Discussion with Young Male Laboratory Assistant. He Shows Her Data Charts on a Clipboard, She Analyzes it and Enters It into Her Computer.
Activities Underway To Resume US Phase III Trials

The US FDA has removed a clinical hold for Kolon TissueGene Inc.’s allogeneic cell and gene therapy for knee osteoarthritis Invossa (TissueGene-C; tonogenchoncel-L), which was undergoing Phase III trials.

The long-awaited decision has provided a glimpse of light for Kolon TissueGene, formerly known as TissueGene Inc., and parent...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia